As advised via PHARMAC Tender Results of 29 November 2019 there is to be a change in the listing and future sole supply of Olopatadine eye drops.

New listing from 1 May 2020

Olopatadine Eye Drops 0.1% 5 ml OP                                                                                 Pharmacode TBA                  Schedule price $2.20

Incumbent brand

Patanol Eye drops 0.1% 5 ml OP                                                                                          Pharmacode 2099365         Schedule price $10.00

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 October 2020.

Brand switch fee not notified in Tender results.

As of the date of this notification ProPharma / PWR cannot accept Patanol for credit under any circumstances.

From 1 May 2020 community pharmacies dispensing Olopatadine Eye Drops will need to support patients changing to the new brand and manage stock during the 5 month transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.


Benefit of staying with incumbent while stock remains available are minimal, but every cent counts:-

Patanol : – Dispensing 1 OP at $10.00 x 3% = $0.30 plus  $0.255 (pack fee) giving you $0.5550

Compared to $2.20 x 3% = $0.066 plus $2.55 (pack fee) giving you $0.3210.

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 October 2020.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 October 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author